Pathfinder Cell Therapy, Inc.

OTCPK:PFND Stock Report

Market Cap: US$667.0

Pathfinder Cell Therapy Balance Sheet Health

Financial Health criteria checks 0/6

Insufficient data to determine the health of Pathfinder Cell Therapy

Key information

n/a

Debt to equity ratio

n/a

Debt

Interest coverage ration/a
Cashn/a
Equityn/a
Total liabilitiesn/a
Total assetsn/a

Recent financial health updates

No updates

Recent updates

No updates

In this section we usually analyse Pathfinder Cell Therapy's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Pathfinder Cell Therapy has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.

Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if PFND's short term assets cover its short term liabilities.

Long Term Liabilities: Insufficient data to determine if PFND's short term assets cover its long term liabilities.


Debt to Equity History and Analysis

Debt Level: Insufficient data to calculate PFND's net debt to equity ratio to determine if it is satisfactory.

Reducing Debt: Insufficient data to determine if PFND's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: Insufficient data to determine if PFND's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if PFND's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies